Characteristics of chronic rejection in heart transplantation: Important elements of pathogenesis and future treatments

Circulation Journal

Volumn 74, Issue 2, 2010, Pages 233-239

  Suzuki, Jun Ichi ^a   Isobe, Mitsuaki ^b   Morishita, Ryuichi ^c   Nagai, Ryozo ^d  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

Arteriosclerosis; Gene therapy; Transplantation

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CELL ADHESION MOLECULE; CHEMOKINE; CYCLOSPORIN A; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANGIOCARDIOGRAPHY; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CHRONIC GRAFT REJECTION; GENE THERAPY; GENETIC TRANSFECTION; HEART TRANSPLANTATION; HUMAN; PATHOGENESIS; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CARDIOVASCULAR AGENTS; CHRONIC DISEASE; CORONARY ARTERY DISEASE; GENE THERAPY; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TRANSPLANTATION, HOMOLOGOUS;

EID: 75749115597     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0809     Document Type: Review

References (80)

1. Taylor DO, Stehlik J, Edwards LB, Aurora P, Christie JD, Dobbels F, et al. Registry of the international society for heart and lung transplantation: Twenty-sixth official adult heart transplant report-2009. J Heart Lung Transplant 2009; 28: 1007-1022.
2. Vega JD, Moore J, Murray S, Chen JM, Johnson MR, Dyke DB. Heart transplantation in the United States, 1998-2007. Am J Transplant 2009; 9: 932-941.
3. Mitchell RN. Graft vascular disease: Immune response meets the vessel wall. Annu Rev Pathol 2009; 4: 19-47.
4. Schmauss D, Weis M. Cardiac allograft vasculopathy: Recent developments. Circulation 2008; 117: 2131-2141.
5. Ramzy D, Rao V, Brahm J, Miriuka S, Delgado D, Ross HJ. Cardiac allograft vasculopathy: A review. Can J Surg 2005; 48: 319-327.
6. Mitchell R, Libby P. Vascular remodeling in transplant vasculopathy. Circ Res 2007; 100: 967-978.
7. Libby P, Pober J. Chronic rejection. Immunity 2001; 14: 387-397.
8. Furukawa Y, Libby P, Stinn J, Becker G, Mitchell R. Cold ischemia enhances cytokine/cell adhesion molecule expression and induces graft arterial disease in isografts, but does not accentuate alloimmune responses of nonimmunosuppressed hosts. Am J Pathol 2002; 160: 1077-1087.
9. Dhaliwal A, Thohan V. Cardiac allograft vasculopathy: The Achilles heel of long-term survival after cardiac transplantation. Curr Atheroscler Rep 2006; 8: 119-130.
10. Suzuki J, Isobe M, Aikawa M, Kawauchi M, Shiojima I, Kobayashi N, et al. Nonmuscle and smooth muscle myosin heavy chain expression in rejected cardiac allografts: A study in rat and monkey models. Circulation 1996; 94: 1118-1124.
11. Shah R, Mitchell R. The role of stem cells in the response to myocardial and vascular wall injury. Cardiovasc Pathol 2005; 14: 225-231.
12. Tuzcu E, Kapadia S, Sachar R, Ziada K, Crowe T, Feng J, et al. Intravascular ultrasound evidence of angiographically silent progression in coronary atherosclerosis predicts long-term morbidity and mortality after cardiac transplantation. J Am Coll Cardiol 2005; 45: 1538-1542.
13. Bogot NR, Durst R, Shaham D, Admon D. Cardiac CT of the transplanted heart: Indications, technique, appearance, and complications. Radiographics 2007; 27: 1297-1309.
14. Michaels P, Espejo M, Kobashigawa J, Alejos J, Burch C, Takemoto S, et al. Humoral rejection in cardiac transplantation: Risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 2003; 22: 58-69.
15. Wehner J, Morrell C, Reynolds T, Rodriguez E, Baldwin W. Antibody and complement in transplant vasculopathy. Circ Res 2007; 100: 191-203.
16. Caforio A, Tona F, Fortina A, Angelini A, Piaserico S, Gambino A, et al. Immune and nonimmune predictors of cardiac allograft vasculopathy onset and severity: Multivariate risk factor analysis and role of immunosuppression. Am J Transplant 2004; 4: 962-970.
17. el-Sawy T, Fahmy N, Fairchild R. Chemokines: Directing leukocyte infiltration into allografts. Curr Opin Immunol 2002; 14: 562-568.
18. Valantine H. The role of viruses in cardiac allograft vasculopathy. Am J Transplant 2004; 4: 169-177.
19. Streblow D, Kreklywich C, Andoh T, Moses A, Dumortier J, Smith PP, et al. The role of angiogenic and wound repair factors during CMV-accelerated transplant vascular sclerosis in rat cardiac transplants. Am J Transplant 2008; 8: 277-287.
20. Isobe M, Kosuge H, Suzuki J. T cell costimulation in the development of cardiac allograft vasculopathy: Potential targets for therapeutic interventions. Arterioscler Thromb Vasc Biol 2006; 26: 1447-1456.
21. Denton M, Davis S, Baum M, Melter M, Reinders M, Exeni A, et al. The role of the graft endothelium in transplant rejection: Evidence that endothelial activation may serve as a clinical marker for the development of chronic rejection. Pediatr Transplant 2000; 4: 252-260.
22. Dietrich H, Hu Y, Zou Y, Dirnhofer S, Kleindienst R, Wick G, et al. Mouse model of transplant arteriosclerosis: Role of intercellular adhesion molecule-1. Arterioscler Thromb Vasc Biol 2000; 20: 343-352.
23. Isobe M, Yagita H, Okumura K, Ihara A. Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science 1992; 255: 1125-1127.
24. Suzuki J, Isobe M, Yamazaki S, Sekiguchi M. Inhibition of accelerated coronary atherosclerosis with short-term blockade of intercellular adhesion molecule-1 and lymphocyte function-associated antigen-1 in a heterotopic murine model of heart transplantation. J Heart Lung Transplant 1997; 16: 1141-1148.
25. Furukawa Y, Mandelbrot D, Libby P, Sharpe A, Mitchell R. Association of B7-1 costimulation with the development of graft arterial disease: Studies using mice lacking B7-1, B7-2, or B7-1/B7-2. Am J Pathol 2000; 157: 473-484.
26. Kosuge H, Suzuki J, Gotoh R, Koga N, Ito H, Isobe M, et al. The induction of immunological tolerance to cardiac allograft by simultaneous blockade of inducible co-stimulator (ICOS) and CTLA4 pathway. Transplantation 2003; 75: 1374-1379.
27. Kosuge H, Suzuki J, Haraguchi G, Koga N, Maejima Y, Inobe M, et al. Critical role of inducible costimulator signaling in the development of arteriosclerosis. Arterioscler Thromb Vasc Biol 2006; 26: 2660-2665.
28. Yamazaki S, Isobe M, Suzuki J, Tojo S, Horie S, Okubo Y, et al. Role of selectin-dependent adhesion in cardiac allograft rejection. J Heart Lung Transplant 1998; 17: 1007-1016.
29. Kosuge H, Suzuki J, Kakuta T, Haraguchi G, Koga N, Futamatsu H, et al. Attenuation of graft arterial disease by manipulation of the LIGHT pathway. Arterioscler Thromb Vasc Biol 2004; 24: 1409-1415.
30. Saiki H, Suzuki J, Kosuge H, Haraguchi G, Haga T, Maejima Y, et al. Blockade of the 4-1BB pathway attenuates graft arterial disease in cardiac allografts. Int Heart J 2008; 49: 105-118.
31. Koga N, Suzuki J, Kosuge H, Haraguchi G, Onai Y, Futamatsu H, et al. The blockade of the interaction between PD-1 and PD-L1 accelerates graft arterial disease in cardiac allografts. Arterioscler Thromb Vasc Biol 2004; 24: 2057-2062.
32. Tellides G, Pober J. Interferon-γ axis in graft arteriosclerosis. Circ Res 2007; 100: 622-632.
33. Nagano H, Mitchell R, Taylor M, Hasegawa S, Tilney N, Libby P. Interferon-γ deficiency prevents coronary arteriosclerosis but not myocardial rejection in transplanted mouse hearts. J Clin Invest 1997; 100: 550-557.
34. Gerdes N, Sukhova G, Libby P, Reynolds R, Young J, Schönbeck U. Expression of interleukin-18 and functional IL-18 receptor on vascular endothelial cells, smooth muscle cells, and macrophages: Implication for atherogenesis. J Exp Med 2002; 195: 245-257.
35. Tellides G, Tereb D, Kirkiles-Smith N, Kim R, Wilson JH, Schechner JS, et al. Interferon-γ elicits arteriosclerosis in the absence of leukocytes. Nature 2000; 403: 207-211.
36. Suzuki J, Cole S, Batirel S, Kosuge H, Shimizu K, Isobe M, et al. Tumor necrosis factor receptor-1 and -2 double deficiency reduces graft arterial disease in murine cardiac allografts. Am J Transplant 2003; 3: 968-976.
37. Nelson P, Krensky A. Chemokines, chemokine receptors, and allograft rejection. Immunity 2001; 14: 377-386.
38. von Hundelshausen P, Weber K, Huo Y, Proudfoot A, Nelson P, Ley K, et al. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 2001; 103: 1772-1777.
39. Zhao D, Hu Y, Miller G, Luster A, Mitchell R, Libby P. Differential expression of the IFN-γ-inducible CXCR3-binding chemokines, IFN-inducible protein 10, monokine induced by IFN, and IFN-inducible T cell α chemoattractant in human cardiac allografts: Association with cardiac allograft vasculopathy and acute rejection. J Immunol 2002; 169: 1556-1560.
40. van Loosdregt J, van Oosterhout M, Bruggink A, van Wichen D, van Kuik J, de Koning E, et al. The chemokine and chemokine receptor profile of infiltrating cells in the wall of arteries with cardiac allograft vasculopathy is indicative of a memory T-helper 1 response. Circulation 2006; 114: 1599-1607.
41. Gao W, Topham P, King J, Smiley S, Csizmadia V, Lu B, et al. Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection. J Clin Invest 2000; 105: 35-44.
42. Shimizu K, Mitchell R. Stem cell origins of intimal cells in graft arterial disease. Curr Atheroscler Rep 2003; 5: 230-237.
43. Hillebrands J, Klatter F, Rozing J. Origin of vascular smooth muscle cells and the role of circulating stem cells in transplant arteriosclerosis. Arterioscler Thromb Vasc Biol 2003; 23: 380-387.
44. Hillebrands J, Klatter F, van den Hurk BM, Popa E, Nieuwenhuis P, Rozing J. Origin of neointimal endothelium and α-actin-positive smooth muscle cells in transplant arteriosclerosis. J Clin Invest 2001; 107: 1411-1422.
45. Glaser R, Lu M, Narula N, Epstein J. Smooth muscle cells, but not myocytes, of host origin in transplanted human hearts. Circulation 2002; 106: 17-19.
46. Minami E, Laflamme M, Saffitz J, Murry C. Extracardiac progenitor cells repopulate most major cell types in the transplanted human heart. Circulation 2005; 112: 2951-2958.
47. Wenke K, Meiser B, Thiery J, Nagel D, von Scheidt W, Krobot K, et al. Simvastatin initiated early after heart transplantation: 8-year prospective experience. Circulation 2003; 107: 93-97.
48. Schroeder JS, Gao SZ, Alderman EL, Hunt SA, Johnstone I, Boothroyd DB, et al. A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. N Engl J Med 1993; 328: 164-170.
49. Steinhauff S, Pehlivanli S, Bakovic-Alt R, Meiser BM, Becker BF, von Scheidt W, et al. Beneficial effects of quinaprilat on coronary vasomotor function, endothelial oxidative stress, and endothelin activation after human heart transplantation. Transplantation 2004; 77: 1859-1865.
50. Bae JH, Rihal CS, Edwards BS, Kushwaha SS, Mathew V, Prasad A, et al. Association of angiotensin-converting enzyme inhibitors and serum lipids with plaque regression in cardiac allograft vasculopathy. Transplantation 2006; 82: 1108-1111.
51. Erinc K, Yamani MH, Starling RC, Crowe T, Hobbs R, Bott-Silverman C, et al. The effect of combined angiotensin-converting enzyme inhibition and calcium antagonism on allograft coronary vasculopathy validated by intravascular ultrasound. J Heart Lung Transplant 2005; 24: 1033-1038.
52. Fang JC, Kinlay S, Beltrame J, Hikiti H, Wainstein M, Behrendt D, et al. Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: A randomised trial. Lancet 2002; 359: 1108-1113.
53. Iwanaga K, Hasegawa T, Hultquist DE, Harada H, Yoshikawa Y, Yanamadala S, et al. Riboflavin-mediated reduction of oxidant injury, rejection, and vasculopathy after cardiac allotransplantation. Transplantation 2007; 83: 747-753.
54. Segovia J, Gomez-Bueno M, Alonso-Pulpon L. Treatment of allograft vasculopathy in heart transplantation. Expert Opin Pharmacother 2006; 7: 2369-2383.
55. Kobashigawa JA, Patel J, Furukawa H, Moriguchi JD, Yeatman L, Takemoto S, et al. Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients. J Heart Lung Transplant 2006; 25: 434-439.
56. Kobashigawa JA, Tobis JM, Mentzer RM, Valantine HA, Bourge RC, Mehra MR, et al. Mycophenolate mofetil reduces intimal thickness by intravascular ultrasound after heart transplant: Reanalysis of the multicenter trial. Am J Transplant 2006; 6: 993-997.
57. Kaczmarek I, Ertl B, Schmauss D, Sadoni S, Knez A, Daebritz S, et al. Preventing cardiac allograft vasculopathy: Long-term beneficial effects of mycophenolate mofetil. J Heart Lung Transplant 2006; 25: 550-556.
58. Mancini D, Pinney S, Burkhoff D, LaManca J, Itescu S, Burke E, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003; 108: 48-53.
59. Keogh A, Richardson M, Ruygrok P, Spratt P, Galbraith A, O'Driscoll G, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: A randomized clinical trial. Circulation 2004; 110: 2694-2700.
60. Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler HA, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847-858.
61. Kawai T, Cosimi AB, Wee SL, Houser S, Andrews D, Sogawa H, et al. Effect of mixed hematopoietic chimerism on cardiac allograft survival in cynomolgus monkeys. Transplantation 2002; 73: 1757-1764.
62. Isobe M, Suzuki J. New approaches to the management of acute and chronic cardiac allograft rejection. Jpn Circ J 1998; 62: 315-327.
63. Morishita R. Perspective in progress of cardiovascular gene therapy. J Pharmacol Sci 2004; 95: 1-8.
64. Tsai LH, Harlow E, Meyerson M. Isolation of the human cdk2 gene that encodes the cycline A and adenovirus E1A associated p33 kinase. Nature 1991; 353: 174-177.
65. Suzuki J, Isobe M, Morishita R, Aoki M, Horie S, Okubo Y, et al. Prevention of graft coronary arteriosclerosis by antisense cdk2 kinase oligonucleotide. Nat Med 1997; 3: 900-903.
66. Morishita R, Gibbons GH, Ellison KE, Nakajima M, Zhang L, Kaneda Y, et al. Single intraluminal delivery of antisense cdc 2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci USA 1993; 90: 8474-8478.
67. Suzuki J, Isobe M, Morishita R, Nishikawa T, Amano J, Kaneda Y. Prevention of cardiac allograft arteriosclerosis using antisense proliferating-cell nuclear antigen oligonucletide. Transplantation 2000; 70: 398-400.
68. Geng YJ, Libby P. Evidence for apoptosis in advanced human atheroma: Colocalization with interleukin-1 beta-converting enzyme. Am J Pathol 1995; 147: 251-266.
69. Suzuki J, Isobe M, Morishita R, Nishikawa T, Amano J, Kaneda Y. Antisense bcl-x oligonucleotide induces apoptosis and prevents arterial neointimal formation in murine cardiac allografts. Cardiovasc Res 2000; 45: 783-787.
70. Morishita R, Gibbons GH, Horiuchi M, Ellison KE, Nakajima M, Chang L, et al. A gene strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA 1995; 92: 5855-5859.
71. Kawauchi M, Suzuki J, Morishita R, Wada Y, Izawa A, Tomita N, et al. Gene therapy for attenuating cardiac allograft arteriopathy using ex vivo E2F decoy transfection by HVJ-AVE-liposome method in mice and nonhuman primates. Circ Res 2000; 87: 1063-1068.
72. Barnes PJ, Karin M. Nuclear factor-kappaB: A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066-1071.
73. Suzuki J, Morishita R, Amano J, Kaneda Y, Isobe M. Decoy against nuclear factor-kappa B attenuates myocardial cell infiltration and arterial neointimal formation in murine cardiac allografts. Gene Ther 2000; 7: 1847-1852.
74. Mann MJ, Whittemore AD, Donaldson MC, Belkin M, Conte MS, Polak JF, et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: The PREVENT single-centre, randomised, controlled trial. Lancet 1999; 354: 1493-1498.
75. Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson TB Jr, Lorenz TJ, et al. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: A randomized controlled trial. JAMA 2005; 294: 2446-2454.
76. Suzuki J, Ito H, Gotoh R, Morishita R, Egashira K, Isobe M. Initial clinical cases using an NF-κB decoy at the site of the coronary stenting for prevention of restenosis. Circ J 2004; 68: 270-271.
77. Egashira K, Suzuki J, Ito H, Aoki M, Isobe M, Morishita R for INDOR Study Group. Long-term follow up of initial clinical cases with NF-κB decoy oligodeoxynucleotide transfection at the site of the coronary stenting. J Gene Med 2008; 10: 805-809.
78. Suzuki J, Tezuka D, Morishita R, Isobe M. An initial case of suppressed restenosis with NF-κB decoy transfection after PCI. J Gene Med 2009; 11: 89-91.
79. Kitamura S, Nakatani T, Kato T, Yanase M, Kobayashi J, Nakajima H, et al. Hemodynamic and echocardiographic evaluation of orthotopic heart transplantation with the modified bicaval anastomosis technique. Circ J 2009; 73: 1235-1239.
80. Nakatani T. Heart transplantation. Circ J 2009; 73: A-55-A-60.